• Cereno Scientific will host US investigators in Boston on December 2, 2026, to support its Phase IIb EPIMODE trial in pulmonary arterial hypertension.
• Up to 15 sites are expected to activate by year-end 2026; more than 50% of planned sites should activate by March 2027.
• Recruitment is targeted for completion during 2027, with topline results expected in the fourth quarter of 2028, subject to recruitment timelines.
• The placebo-controlled trial will evaluate CS1 added to standard care, enrolling approximately 126 patients across about 68 sites in 12 countries.
• Previously reported Phase IIa findings showed encouraging efficacy signals, including improved heart function and quality of life, with a favorable safety profile.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cereno Scientific AB published the original content used to generate this news brief on November 02, 2026, and is solely responsible for the information contained therein.